Custom-Made melanoma vaccine shows promise in early trial

NCT ID NCT01970358

Completed ⭐️ VACCINE ⭐️ Sponsor: Patrick Ott, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune responses. The approach is highly individualized, aiming to train the body to fight future cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized NeoAntigen Cancer Vaccine (peptides plus Poly-ICLC adjuvant)
What this could lead to: If this works, it could pave the way for a personalized vaccine that trains the immune system to recognize and attack a patient's unique melanoma cells, potentially preventing the cancer from coming back.
What could go wrong: This is a very early phase 1 trial with only 15 participants, so the main goal is safety and feasibility, not effectiveness. The vaccine is custom-made for each person, which is complex and may not be possible for everyone. There is also a risk of immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.